Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.50 |
| ▸ | KLK3 | P07288 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | C1R | P00736 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.40 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282876 | 0.90 | ELANE (0.62) | ELANEKLK3TYMSMEN1KMT2A | |
| SCHEMBL10662992 | 0.78 | ELANE (0.63) | ELANEKLK3TYMSMEN1KMT2A | |
| SCHEMBL912480 | 0.75 | KMT2A (0.73) | ELANEKLK3MEN1KMT2AMAPT | |
| SCHEMBL31489848 | 0.75 | MEN1 (0.58) | ELANEKLK3MEN1KMT2AMAPT | |
| SCHEMBL17770598 | 0.75 | MEN1 (0.58) | ELANEKLK3MEN1KMT2AMAPT | |
| SCHEMBL26672077 | 0.74 | TYMS (0.42) | ELANEKLK3TYMSMEN1KMT2A | |
| SCHEMBL914145 | 0.73 | F7 (0.59) | ELANEKLK3TYMSMEN1KMT2A | |
| SCHEMBL7319447 | 0.72 | MEN1 (0.42) | ELANEKLK3TYMSMEN1KMT2A | |
| SCHEMBL914648 | 0.72 | MEN1 (0.48) | ELANEKLK3TYMSMEN1KMT2A | |
| SCHEMBL914707 | 0.71 | ELANE (0.67) | ELANEKLK3MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150203469-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | CELGENE CORPORATION | 2015-07-23 | — | — | US | claimed |
| EP-2892887-B1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | CELGENE CORP (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20180093965-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE AND METHODS OF PREPARATION THEREOF | CELGENE CORP (US) | 2018-04-05 | — | — | US | disclosed |
| US-9682952-B2 | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof | CELGENE CORPORATION (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682952-B2 | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof | CELGENE CORPORATION (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150203469-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | CELGENE CORPORATION | 2015-07-23 | — | — | US | disclosed |
| US-20150203469-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | CELGENE CORPORATION | 2015-07-23 | — | — | US | disclosed |
| EP-2892887-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | Celgene Corporation (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014039421-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | CELGENE CORPORATION (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203469-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | AQP3, CYP2D6, CYP3A5 | ELANE 4693/4885KLK3 720/4885TYMS 1174/4885 |
| US-20180093965-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE AND METHODS OF PREPARATION THEREOF | CYP2D6, AQP3, CYP3A5 | ELANE 4672/4885KLK3 740/4885TYMS 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.